AU2015264021B2 - Imidazole derivatives as formyl peptide receptor modulators - Google Patents

Imidazole derivatives as formyl peptide receptor modulators Download PDF

Info

Publication number
AU2015264021B2
AU2015264021B2 AU2015264021A AU2015264021A AU2015264021B2 AU 2015264021 B2 AU2015264021 B2 AU 2015264021B2 AU 2015264021 A AU2015264021 A AU 2015264021A AU 2015264021 A AU2015264021 A AU 2015264021A AU 2015264021 B2 AU2015264021 B2 AU 2015264021B2
Authority
AU
Australia
Prior art keywords
unsubstituted
alkyl
substituent
heterocycle
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015264021A
Other languages
English (en)
Other versions
AU2015264021A1 (en
Inventor
Richard L. Beard
Tien T. Duong
Michael E. Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2015264021A1 publication Critical patent/AU2015264021A1/en
Application granted granted Critical
Publication of AU2015264021B2 publication Critical patent/AU2015264021B2/en
Priority to AU2020203420A priority Critical patent/AU2020203420B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015264021A 2014-05-21 2015-05-21 Imidazole derivatives as formyl peptide receptor modulators Active AU2015264021B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203420A AU2020203420B2 (en) 2014-05-21 2020-05-25 Imidazole derivatives as formyl peptide receptor modulators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462001188P 2014-05-21 2014-05-21
US62/001,188 2014-05-21
PCT/US2015/032069 WO2015179707A1 (en) 2014-05-21 2015-05-21 Imidazole derivatives as formyl peptide receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203420A Division AU2020203420B2 (en) 2014-05-21 2020-05-25 Imidazole derivatives as formyl peptide receptor modulators

Publications (2)

Publication Number Publication Date
AU2015264021A1 AU2015264021A1 (en) 2016-12-01
AU2015264021B2 true AU2015264021B2 (en) 2020-02-27

Family

ID=53276329

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015264021A Active AU2015264021B2 (en) 2014-05-21 2015-05-21 Imidazole derivatives as formyl peptide receptor modulators
AU2020203420A Active AU2020203420B2 (en) 2014-05-21 2020-05-25 Imidazole derivatives as formyl peptide receptor modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203420A Active AU2020203420B2 (en) 2014-05-21 2020-05-25 Imidazole derivatives as formyl peptide receptor modulators

Country Status (12)

Country Link
US (2) US10301269B2 (ja)
EP (1) EP3145916B1 (ja)
JP (1) JP6660889B2 (ja)
KR (1) KR20170005121A (ja)
CN (1) CN106458921B (ja)
AU (2) AU2015264021B2 (ja)
BR (1) BR112016027133A8 (ja)
CA (1) CA2948876A1 (ja)
DK (1) DK3145916T3 (ja)
ES (1) ES2788700T3 (ja)
RU (1) RU2748652C2 (ja)
WO (1) WO2015179707A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
CN107714683A (zh) * 2013-03-06 2018-02-23 阿勒根公司 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途
WO2015077451A1 (en) 2013-11-21 2015-05-28 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
BR112016027133A8 (pt) 2014-05-21 2021-06-29 Allergan Inc derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
CN109641857A (zh) * 2016-04-12 2019-04-16 阿勒根公司 作为n-甲酰基肽受体调节剂的苯基脲衍生物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
KR20060130064A (ko) * 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도
CN102516240A (zh) 2004-01-06 2012-06-27 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
WO2007086584A1 (ja) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
EP2057140B1 (en) * 2006-08-24 2012-08-08 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2009000748A1 (en) 2007-06-27 2008-12-31 Solvay Fluor Gmbh Preparation of compounds with a perfluoroalkylsulfonyl group
KR20100031639A (ko) * 2007-07-09 2010-03-23 아스트라제네카 아베 증식성 질환의 치료용 삼중 치환된 피리미딘 유도체
CN101998680B (zh) * 2009-08-24 2016-01-13 中兴通讯股份有限公司 帧序列号的发送方法及节点b和服务无线网络控制器
AU2011336973A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
EP2673263A1 (en) 2011-02-11 2013-12-18 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
EP2731931A1 (en) 2011-07-11 2014-05-21 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
HUE040145T2 (hu) * 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8729096B2 (en) * 2012-02-16 2014-05-20 Allergan, Inc. Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators
JP2015520130A (ja) 2012-04-16 2015-07-16 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ホルミルペプチド受容体２調節物質としての（２−ウレイドアセトアミド）アルキル誘導体
CN107714683A (zh) 2013-03-06 2018-02-23 阿勒根公司 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途
CA3133264A1 (en) 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
JP6653253B2 (ja) 2013-07-16 2020-02-26 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体
WO2015077451A1 (en) 2013-11-21 2015-05-28 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
US9920013B2 (en) 2014-01-29 2018-03-20 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
WO2015116574A1 (en) 2014-01-29 2015-08-06 Allergan, Inc. Urea hydantoin derivatives as formyl peptide modulators
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
BR112016027133A8 (pt) 2014-05-21 2021-06-29 Allergan Inc derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
CN109715602A (zh) 2016-03-28 2019-05-03 阿勒根公司 苯基脲衍生物作为n-甲酰肽受体调节剂
CN109641857A (zh) 2016-04-12 2019-04-16 阿勒根公司 作为n-甲酰基肽受体调节剂的苯基脲衍生物

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
CAS REG NO. 1444645-49-1, STN Entry Date: 16 July 2013; Urea, N-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG NO. 1466794-83-1, STN Entry Date: 01 November 2013; Urea, N-[4-(1-aminoethyl)phenyl]-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG NO. 1481663-62-0, STN Entry Date: 27 November 2013; Urea, N-[4-(aminomethyl)phenyl]-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1378385-01-3, STN Entry Date: 14 June 2012; Urea, N-(3-chloro-4-methylphenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1378391-54-8, STN Entry Date: 14 June 2012; Urea, N-(4-aminophenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1378482-06-4, STN Entry Date: 14 June 2012; Urea, N-(4-acetylphenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1378970-43-4, STN Entry Date: 15 June 2012; Urea, N-(1H-imidazol-2-ylmethyl)-N′-(4-methoxyphenyl)- *
CAS REG. NO. 1379170-34-9, STN Entry Date: 17 June 2012; Urea, N-(1H-imidazol-2-ylmethyl)-N′-(4-methylphenyl)- *
CAS REG. NO. 1423602-69-0, STN Entry Date: 14 March 2013; Urea, N-[1,1′-biphenyl]-4-yl-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1424349-94-9, STN Entry Date: 15 March 2013; Urea, N-(4-bromo-2-chlorophenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1477542-70-3, STN Entry Date: 21 November 2013; Urea, N-(3,4-dichlorophenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1479406-85-3 , STN Entry Date : 24 November 2013; Urea, N-(1H-imidazol-2-ylmethyl)-N′-[4-(trifluoromethyl)phenyl]- *
CAS REG. NO. 1479511-24-4, STN Entry Date: 24 November 2013; Urea, N-[4-(1-hydroxyethyl)phenyl]-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1483807-63-1, STN Entry Date: 30 November 2013; Urea, N-(4-chlorophenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1491331-55-5, STN Entry Date: 11 December 2013; Urea, N-(2,4-difluorophenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1492584-16-3, STN Entry Date: 12 December 2013; Urea, N-(4-fluorophenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1496192-08-5, STN Entry Date: 17 December 2013; Benzeneacetic acid, 4-[[[(1H-imidazol-2-ylmethyl)amino]carbonyl]amino]- *
CAS REG. NO. 1497615-40-3, STN Entry Date: 19 December 2013; Urea, N-(4-butylphenyl)-N′-(1H-imidazol-2-ylmethyl)- *
CAS REG. NO. 1549726-72-8, STN Entry Date: 20 February 2014; Benzenepropanoic acid, 4-[[[(1H-imidazol-2-ylmethyl)amino]carbonyl]amino]- *
CAS REG. NO.1428092-78-7, STN Entry Date:11 April 2013; Urea, N-(2,4-dichlorophenyl)-N′-(1H-imidazol-2-ylmethyl)- *

Also Published As

Publication number Publication date
BR112016027133A2 (pt) 2017-08-15
WO2015179707A1 (en) 2015-11-26
RU2016145596A3 (ja) 2018-11-19
US20170096401A1 (en) 2017-04-06
US10800744B2 (en) 2020-10-13
AU2020203420B2 (en) 2021-12-16
RU2748652C2 (ru) 2021-05-28
JP6660889B2 (ja) 2020-03-11
BR112016027133A8 (pt) 2021-06-29
US10301269B2 (en) 2019-05-28
CN106458921A (zh) 2017-02-22
US20200115346A1 (en) 2020-04-16
CN106458921B (zh) 2020-03-24
EP3145916A1 (en) 2017-03-29
CA2948876A1 (en) 2015-11-26
DK3145916T3 (da) 2020-05-11
JP2017520528A (ja) 2017-07-27
AU2020203420A1 (en) 2020-06-11
EP3145916B1 (en) 2020-02-12
AU2015264021A1 (en) 2016-12-01
KR20170005121A (ko) 2017-01-11
RU2016145596A (ru) 2018-06-21
ES2788700T3 (es) 2020-10-22

Similar Documents

Publication Publication Date Title
AU2020203420B2 (en) Imidazole derivatives as formyl peptide receptor modulators
AU2012336013C1 (en) Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9670150B2 (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
AU2014290618B2 (en) Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
AU2014352922B2 (en) Phenylcarbamate derivatives as formyl peptide receptor modulators
US9604934B2 (en) Urea hydantoin derivatives as formyl peptide modulators
US9920013B2 (en) 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
US20150080466A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
US11286234B2 (en) Phenyl urea derivatives as N-formyl peptide receptor modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)